The new frontier of cancer neuroscience
Understanding complex interactions between cancer and the nervous system may offer new insights into the mechanisms that drive tumour progression
Two studies provide insights into the biological basis of triple-negative breast cancer
Potential novel drivers of chromosome instability and biomarkers of early recurrence were identified
Liquid biopsy for early cancer detection: novel approaches show promising early signals
Novel tests based on epitranscriptomics and cfCTCF-DNA nucleoproteins aim to overcome sensitivity limitations of currently available methods
Early signs of progress in osteosarcoma research
Emerging molecular and spatial approaches are providing new insights into osteosarcoma and identifying potential targets for future therapies
AI for early-phase clinical trials: from hype to proof of concept
Growing experience suggests that artificial intelligence could potentially transform how cancer research is designed and conducted
Is artificial intelligence a reliable partner for multidisciplinary tumour boards?
Real-world findings show moderate-to-high concordance between AI-generated and human experts decisions
New treatment modalities in gastrointestinal malignancies: broadening the therapeutic horizon
Rapid advances in molecular targeting, immunotherapy optimisation and novel drug classes are reshaping gastrointestinal oncology
From bottleneck to breakthrough: rethinking clinical data collection in the age of AI
Every day, clinicians generate thousands of reports containing critical data that will never be analysed. Not because it lacks value — but because extracting it remains a bottleneck.
ctDNA is unlocking new clinical opportunities for liquid biopsy
Testing standardisation and optimal integration for routine clinical use remain challenging
Early-phase studies point to efficacy of a nectin-4-targeting antibody-drug conjugate in cervical cancer
In advanced or metastatic disease, bulumtatug fuvedotin shows promising efficacy and manageable safety